title: Induction therapies in kidney transplantation: the experience of Hospital Pablo Tobon Uribe, Medellín, Colombia 2005-2010.
abstract: BACKGROUND
  Induction therapies in kidney transplantation have led to prescriptions of lower doses of maintenance immunosuppression and fewer acute rejection episodes. We sought to assess the use of an affordable monoclonal antibody in terms of the incidences of rejection episodes as well as graft and patient survivals and cytomegalovirus (CMV) and opportunistic infections among our kidney transplant recipients between August 2005 and December 2010. Data were obtained for patients who had more than 20 months' follow-up.
  
  
  METHODS
  We retrospectively analyzed data from kidney recipients between August 2005 and December 2010, using descriptive statistics and Kaplan-Meier survival analysis. We performed a multivariate analysis with logistic regression for the dependent variables of rejection episodes and death.
  
  
  RESULTS
  Among 425 transplant patients graft survival was 89.2% and patient survival was 94.1% after 76.2% of patients received alemtuzumab, 10.7% daclizumab, 3.6% basiliximab, 2.4% thymoglobulin, and 7%, no induction therapy. Rejection incidence in general in the first year was 10.8% and CMV incidence 10%. There was an increased risk of rejection among subjects without any us with alemtuzumab induction therapy.
  
  
  CONCLUSIONS
  Induction therapies show an important reduction in kidney transplant rejection incidence during the first year, allowing low doses of maintenance immunosuppressants, thereby diminishing long-term adverse effects. Alemtuzumab seemed to be a safe alternative with similar results to those obtained with standard immunosuppression.
authors.affiliation: Transplant Group of the Hospital Pablo Tobon Uribe, Medellín, Colombia.
authors.forename: C
authors.initials: C
authors.lastname: Ocampo
authors.forename: A
authors.initials: A
authors.lastname: Aristizabal
authors.forename: J
authors.initials: J
authors.lastname: Nieto
authors.forename: H
authors.initials: H
authors.lastname: Abadia
authors.forename: W
authors.initials: W
authors.lastname: Angel
authors.forename: C
authors.initials: C
authors.lastname: Guzman
authors.forename: A
authors.initials: A
authors.lastname: Mena
authors.forename: J
authors.initials: J
authors.lastname: Vanegas
authors.forename: C
authors.initials: C
authors.lastname: Velez
authors.forename: C
authors.initials: C
authors.lastname: Aguirre
authors.forename: C
authors.initials: C
authors.lastname: Yepes
authors.forename: G
authors.initials: G
authors.lastname: Zuluaga
mesh_terms: D000328:Adult; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D000077552:Basiliximab; D003105:Colombia; D003586:Cytomegalovirus Infections; D000077561:Daclizumab; D005260:Female; D006084:Graft Rejection; D006085:Graft Survival; D006761:Hospitals; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000379:methods*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D012044:Regression Analysis; D051437:Renal Insufficiency / Q000401:mortality / Q000628:therapy*; D012189:Retrospective Studies; D012306:Risk; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000961:Antilymphocyte Serum; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D000074323:Alemtuzumab; D000077552:Basiliximab; D000077561:Daclizumab; C512542:thymoglobulin